Kisspeptin: The Gate of the Reproductive Axis

The short version

Kisspeptin is a family of neuropeptides encoded by the KISS1 gene. The main isoform studied in humans is kisspeptin-54, also historically called metastin. A shorter active fragment, kisspeptin-10, carries the same receptor-binding tail and is used in many research protocols. What these peptides do is act at the top of the reproductive hormone cascade: they bind KISS1R receptors on hypothalamic GnRH neurons, triggering pulsatile release of GnRH and from there LH, FSH and downstream sex steroids ^[12].

No kisspeptin product is approved by any regulator for any indication as of 2025 ^[9]. Controlled human trials have demonstrated LH stimulation, restored menstrual cycles in hypothalamic amenorrhea, and effective oocyte-maturation triggering in IVF ^[8][10][11]. Some work also links kisspeptin to sexual motivation at the brain level. The entire clinical picture, however, is investigational — Phase 1 and Phase 2 work conducted under medical supervision with pharmaceutical-grade material. Research-grade kisspeptin from unregulated suppliers carries no quality guarantee. This page summarizes the studies; it lists no human dose and gives no advice.

What it is

Kisspeptin is produced from a 145-amino-acid precursor encoded by the KISS1 gene and cleaved to multiple isoforms: kisspeptin-54 (the full-length secreted form, also called KP-54 or metastin), kisspeptin-14 (KP-14), kisspeptin-13 (KP-13) and kisspeptin-10 (KP-10). All isoforms share a conserved C-terminal Arg-Phe-amide motif required for KISS1R binding. KP-10 sequence: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2. The receptor, KISS1R (formerly GPR54), is a Gq/11-coupled G protein-coupled receptor. Kisspeptin does not itself supply LH, FSH or sex steroids; it stimulates the body's own GnRH neurons to do that work.

How it works

Kisspeptin binds KISS1R on hypothalamic GnRH neurons. Receptor activation drives a phospholipase C / IP3 / intracellular-calcium cascade that depolarizes the neuron and triggers pulsatile GnRH release. GnRH then signals the pituitary to release LH and FSH, driving downstream gonadal steroidogenesis — testosterone in men, estrogen and progesterone in women.

The primary neurons mediating this effect are the KNDy neurons of the arcuate nucleus — so named because they co-express kisspeptin, neurokinin B and dynorphin — considered the master GnRH pulse generator ^[12].

Because kisspeptin acts on the body's own GnRH neurons, its effect is inherently pulsatile and self-limiting. Sustained or high-dose continuous exposure desensitizes KISS1R and suppresses the downstream response — the peptide's biggest practical limitation and a key clinical observation confirmed in multiple human studies ^[11].

A 2022 neuroimaging study suggests a parallel role for the melanocortin-kisspeptin axis in central sexual brain processing, with MC4R agonism altering amygdala-insula connectivity in women with HSDD ^[2], though direct kisspeptin-specific neuroimaging data are limited.

What the research shows

Intranasal delivery (2025, humans). Intranasal kisspeptin-54 at a primary dose of 12.8 nmol/kg rapidly stimulated LH release in healthy men (+4.4 IU/L), healthy women (+1.4 IU/L) and women with hypothalamic amenorrhea (+4.4 IU/L), with no adverse events. The nasal-spray formulation remained stable for up to 60 days at 4 degrees C — the first clinical demonstration of effective non-invasive delivery ^[8].

Clinical status systematic review (2025). A systematic review identified 29 interventional clinical trials studying kisspeptin across applications including secondary amenorrhea, puberty regulation, ovarian function, fertility, and lactation, with considerably fewer side effects than comparators. No kisspeptin product has received regulatory approval ^[9].

IVF oocyte-maturation trigger (Phase 2, n=60 high-OHSS-risk women). Subcutaneous kisspeptin-54 triggered oocyte maturation in 95% of patients with no case of moderate, severe or critical ovarian hyperstimulation syndrome (OHSS) at any dose. The highest live-birth rate (62%) followed the 9.6 nmol/kg dose ^[10]. This positions kisspeptin as a potentially safer alternative to hCG triggering.

Hypothalamic amenorrhea LH restoration (humans, n=5). Continuous IV kisspeptin-54 restored pulsatile LH secretion in women with hypothalamic amenorrhea: pulses rose from 1.6 to 5.0 per 8 hours (~3-fold) and pulse secretory mass ~6-fold versus vehicle. The highest infusion rate produced tachyphylaxis ^[11].

Kisspeptin-10 in healthy men. IV kisspeptin-10 at 1 ug/kg bolus maximally stimulated LH (4.1 to 12.4 IU/L at 30 min); continuous infusion raised serum testosterone in a dose-dependent manner ^[12].

Reported effects, cautions & safety

The safety cautions for kisspeptin are primarily shaped by its mechanism: it acts on the body's master reproductive switch, is investigational, and desensitizes with repeated exposure.

Cited safety cautions from the literature:

• Investigational and unapproved; unverified quality. No product is approved for any indication. All published human data come from pharmaceutical-grade material under medical supervision. Research-grade kisspeptin carries unverified identity, purity, sterility and concentration ^[9].
• Tachyphylaxis with repeated or continuous dosing. Twice-daily subcutaneous kisspeptin-54 caused acute LH response to fall sharply over two weeks. Continuous IV infusion at the highest rate also desensitized the axis during infusion ^[11]. The peptide partially defeats its own effect under continuous or frequent exposure.
• Acts on the HPG axis. Kisspeptin drives LH, FSH and sex-steroid output. Effects on hormone-sensitive conditions or interactions with hormonal therapy are uncharacterized ^[9].
• Avoid in pregnancy. Kisspeptin is produced in large amounts by the placenta and directly stimulates reproductive hormone signaling; effects of exogenous kisspeptin in pregnancy are uncharacterized ^[9].
• Possible vascular signal. In a mouse model, kisspeptin-10 accelerated atherosclerotic plaque progression — an effect reversed by a GPR54 antagonist. Not characterized in humans ^[9].
• Short-term human safety data only. Long-term safety is unknown. Known hypersensitivity is a contraindication ^[9].

Field reports (anecdotal, not clinical evidence):

Anecdotal accounts in research-use communities describe heightened sexual interest, stronger emotional or romantic response, and improved morning erections in men in the hours after administration. A recurring counterpoint is that many people report no noticeable subjective effect at all, which is consistent with the fact that measurable LH changes on a lab test do not necessarily translate into a felt experience. Reports are sparse because kisspeptin is investigational and not a mass-market product. These are anecdotal observations, reported separately from the cited data, and carry no dosing implication.

Where it fits in desire and arousal research

Kisspeptin occupies a unique position on this desk: it acts upstream of everything, at the gate of the reproductive hormone axis itself ^[12]. Where PT-141 directly stimulates central MC4R for desire signaling and Melanotan II acts non-selectively across melanocortin receptors, kisspeptin talks to the body's own GnRH neurons and lets them generate the hormone signal. Its IVF triggering and hypothalamic-amenorrhea data are the clearest clinical demonstrations of what it does. Its link to desire and arousal specifically remains less directly characterized than PT-141's. See how it lines up on the comparison page.